Business Context and Reporting Period
This Form 8-K filing by Verastem, Inc. (VSTM) reports a significant corporate governance event dated July 29, 2019. The filing announces the appointment of Brian M. Stuglik as Chief Executive Officer and details the terms of his employment agreement.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and appointment terms.
Material Changes
The primary material change is the leadership transition at the CEO level. Brian M. Stuglik, a former Global Vice President and Chief Marketing Officer of Oncology at Eli Lilly and Company, was appointed CEO. He had previously served on the Board of Directors since September 2017 and held a strategic advisory role regarding the commercial organization since May 2019.
Management Commentary and Compensation Details
The employment agreement outlines the following compensation structure for Mr. Stuglik:
- Base Salary: $600,000 annually.
- Annual Bonus: Target of 65% of base salary.
- Time-Based Equity Grant:
- 500,000 incentive stock options at an exercise price of $1.43 per share.
- 270,000 restricted stock units (RSUs).
- Vesting Schedule: 33 1/3% vests on the one-year anniversary, followed by 8.33% every three months thereafter until the third anniversary.
- Performance-Based Equity Grant:
- 200,000 incentive stock options at an exercise price of $1.43 per share.
- Vesting Conditions: 100,000 shares vest upon achieving $20 million in net product revenues of duvelisib; the remaining 100,000 shares vest upon achieving $75 million in net product revenues of duvelisib.
- Severance: Entitlement to severance payments upon termination without Cause or resignation for Good Reason, subject to a release of claims.
Investor Verification Checklist
- Verify the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "Cause" and "Good Reason."
- Confirm the current status of duvelisib net product revenues to assess the likelihood of performance-based equity vesting.
- Review the press release (Exhibit 99.1) for additional strategic context regarding the leadership change.
- Check subsequent filings for any updates to the company's financial position or commercial progress post-appointment.